Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SuperHERO: Radiotherapy Omission for Low-risk HER2-positive Breast Cancer
NCT07895511Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2031
- Countries
- 1
01
Overview
Open-label, single-arm trial in HER2-positive breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Ipsilateral breast recurrence rate at 5 years. Started Oct 2026; status: recruiting.
02
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07895511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07895511.